Friday, 17 Aug 2018

You are here

Opioids No Better than NSAIDs at Chronic Pain

JAMA reports that the SPACE trial demonstrates patients with chronic back or arthritis pain respond equally to 12 months of either opioids or non-opioid (acetaminophen or NSAIDs) analgesics. (citation source:bit.ly/2tpquTM)

The study enrolled 240 patients from the Veterans Affairs primary care colinics with chronic pain in the back, knees or hips.  Patients were randomized to receive opioid vs nonopioid therapy and over 12 months were assessed for pain-related function (Brief Pain Inventory [BPI] . 

All patients followed a treat-to-target strategy aiming for improved pain and function. Opioid patients were given immediate-release morphine, that could be followed by hydrocodone/acetaminophen, or immediate release oxycodone and lastly a long-acting morphine or oxycodone or fentanyl patches.  

The nonopioid group received acetaminophen or a nonsteroidal anti-inflammatory drug. If ineffective therapy could be escalated to gabapentin, topical lidocaine, pregabalin or even tramadol.

The mean age was 58.3 years, 13% were women, and 97.5% completed the trial.

Groups did not significantly differ on pain-related function over 12 months (overall P = .58).  Pain intensity started at 5.4 for both groups but fell significantly more with nonopioids (3.5) than opioids (4.0) after 12 months (overall P = .03).

On the other hand, adverse events were significantly more common in the opioid group (1.8 vs. 0.9;  P = .03).

These results do not support the use of opioids as initial therapy in those with moderate to severe chronic back pain or hip or knee osteoarthritis pain. These results do not apply to management of cancer related pain.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Unsafe Practices with Ambien Use

Ambien (zolpidem) is the most widely used prescription hypnotic sedative since its introduction in 1992 and is currently the fourth most frequently prescribed psychiatric drug (2013). Recent US Food and Drug Administration Drug Safety Communications suggest limitations on use to reduce adverse effects. A study of the Medical Expenditures Survey in 2015 revealed that over 3.8 million adults reported using one or more prescriptions for zolpidem.

Weight Loss Lessens Knee Pain in Obese

Obese knee osteoarthritis (OA) patients who lose > 20% of their weight were in significantly less pain, had better function and improved quality of life. 

Blacks Suffer When Pain is Poorly Defined

Racial discrimination was a key feature at a 2-day summit on pain management and the opioid crisis, hosted by the National Institutes of Health on Thursday and Friday.

Asheley Cockrell Skinner, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, provided a broad overview of racial bias in opioid prescribing.

Prescription Drug Monitoring Programs Fail to Deter Opiate Abuse

A systematic review of prescription drug monitoring programs (PDMPs), advocated in the president's Prescription Drug Abuse Prevention Plan, fails to show evidence of efficacy in preventing nonfatal and fatal overdoses.

Measures of Opioid Misuse Predict Future Opioid Overdose and Death

The current issue of Annals of Internal Medicine examines patterns of potential opioid misuse that are associated with subsequent adverse outcomes nationally.

Researchers analyzed a 5% sample of Medicare beneficiaries who had an opioid prescription, without a cancer diagnosis.  Specifically the sought to correlate a diagnosis of opioid overdose with other measures of opioid misuse including: